Â鶹´«Ã½É«ÇéƬ

Annual Meeting

Type 1 diabetes work
gets special recognition

Kothari named a JLR early-career researcher
Isha Dey
March 1, 2019

For the love of science and a drive to understand disease, Vishal Kothari crossed continents and switched his career path from industry to academia.

Kothari grew up in India, where he completed a bachelor’s degree in pharmacy and a master’s degree in pharmacology. He then worked as a research scientist at Advinus Therapeutics Limited (now ), playing an important role in identifying drugs with improved efficacy for treating diabetes and cardiovascular diseases. This work provided him with much-needed experience, but given the global reach of diabetes and diabetes-associated cardiovascular diseases, Kothari wanted to investigate cardiovascular diseases at the molecular level as a way to pursue better prevention strategies.

Vishal KothariVishal Kothari left a career in industry to study cardiovascular diseases at the molecular level.

“Research in the industry is market-driven, but I wanted to do independent research,” he said.

This passion for scientific research spurred his move from his industry position in India to a Ph.D. program in nutritional sciences at Auburn University in Alabama, where his studies centered on mouse models of diet-induced insulin resistance and insulin signaling.

Since earning his Ph.D., Kothari has worked as a senior research fellow in lab at the University of Washington School of Medicine. His work focuses on the effects of changes in the function and composition of high-density lipoproteins in diabetes-associated risk of cardiovascular diseases such as heart attacks.

In addition to research, Kothari also mentors medical and undergraduate students, which he believes will help him to become an independent researcher. When not in the lab, he likes to travel and hang out with friends.

According to Bornfeldt, Kothari is notable for his “enthusiasm for research, his vision and dedication, his excellence in the lab and his team spirit.”

Addressing small HDLs in heart disease

Cardiovascular disease, or CVD, is the most common cause of death around the world. Factors such as hypertension, diabetes or hyperlipidemia increase the risk of heart disorders. According to the American Heart Association, at least 68 percent of people aged 65 or older with diabetes die from some form of heart disease, and 16 percent die of stroke.

High-density lipoprotein, or HDL, is associated with protection against CVD, perhaps in part by reducing inflammatory activation of macrophages, a key cell type in CVD. However, small populations of HDL also can cause cholesterol depletion and produce an inflammatory response by macrophages under certain conditions.

Vishal Kothari’s research is focused on understanding how small HDLs induce such effects and how Type 1 diabetes mellitus, or T1DM, contributes to this effect, since T1DM increases the risk of CVD including heart attacks. His study has shown that depleting cholesterol by HDL increases proinflammatory responses in macrophages both in vitro and in a transgenic mouse model. His findings further demonstrate that higher levels of small HDL populations, as observed in a mouse model of Type 1 diabetes, can exacerbate inflammatory activation of macrophages and that this process is dependent on a protease called ADAM17.

These findings help provide a better understanding of increased CVD risk in Type 1 diabetes and the possible factors mediating such effects.

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Isha Dey

Isha Dey is a scientist at Thermo Fisher Scientific.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

'You can't afford to be 15 years behind the parasite'
Award

'You can't afford to be 15 years behind the parasite'

Dec. 3, 2024

David Fidock will receive the Alice and C.C. Wang Award in Â鶹´«Ã½É«ÇéƬ Parasitology at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Elucidating how chemotherapy induces neurotoxicity
Award

Elucidating how chemotherapy induces neurotoxicity

Dec. 2, 2024

Andre Nussenzweig will receive the Bert and Natalie Vallee Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

ASBMB committees welcome new members
Announcement

ASBMB committees welcome new members

Nov. 29, 2024

Committee members serve terms of two to five years, and a number of new members have joined. We also thank those whose terms have ended.

Curiosity turned a dietitian into a lipid scientist
Award

Curiosity turned a dietitian into a lipid scientist

Nov. 27, 2024

Judy Storch will receive the Avanti Award in Lipids at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

From receptor research to cancer drug development: The impact of RTKs
Award

From receptor research to cancer drug development: The impact of RTKs

Nov. 26, 2024

Joseph Schlessinger will receive the ASBMB Herbert Tabor Research Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.

Awards for Alrubaye and Dutta; Strochlic named ass't dean
Member News

Awards for Alrubaye and Dutta; Strochlic named ass't dean

Nov. 25, 2024

PSA presents Early Achievement Award for Teaching to Adnan Alrubaye. ASIP honors Anindya Dutta with the Rous–Whipple Award. Drexel names Todd Strochlic assistant dean of curricular integration.